🇺🇸 SECNOVO NORDISK A SDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:00:09·⟳ 抓取 18:10:10 +10m01s·⚡ 决策 09-15 18:13:29 +3m19s·41.9 天前
诺和诺德披露既有回购计划上周执行进展，未新增回购规模或经营信息
该6-K仅是根据MAR安全港规则披露既有回购项目的上周成交明细；150亿丹麦克朗总计划及112亿丹麦克朗子计划均已在2026年2月和5月公布，本次没有扩大授权、加速回购、新经营信息或指引变化，不能形成新的事件驱动edge。
📄 原文NOVO NORDISK A S↗ 原文
----- f6k_091426.htm ----- 6-K 1 f6k_091426.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Novo Nordisk A/S ADR（NVO.US）
6-K仅披露既有150亿丹麦克朗回购计划的上周例行成交，未新增授权、业绩或产品信息；美股盘前虽不可立即成交，但即便等待开盘也缺乏事件驱动edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
诺和诺德披露9月7日至11日按既有授权回购105万股B股，属于例行周度执行报告。回购本身温和正面，但总规模早已公告且本次无新增事项，美股ADR和丹麦B股均不具备可交易的增量预期差。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次披露只证明公司继续执行既有回购，并未改变150亿丹麦克朗授权总额、经营预期或资本配置政策。
- 回购交易区间截至9月11日，公告主要满足法定透明度要求，难以在9月15日盘前产生独立的新催化。
主要风险
- 若投资者将持续回购解读为管理层认为股价低估，可能出现小幅情绪支撑，但该影响已被既有计划和连续披露大幅稀释。
- 一日后FOMC利率决议可能主导医药蓝筹和整体风险偏好，宏观波动不能归因于本次例行回购披露。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-14 · 影响 weakens
6-K未包含提高150亿丹麦克朗授权、新增特别回购、业绩上修或其他足以构成短线利多的内容。
检索:Novo Nordisk September 2026 share repurchase new programme increased authorization guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不改变AVOID结论；不基于例行文件开多，也不设置事件驱动止盈止损。
方向:不使用历史回购先例推断方向；本次核心判断是无新增事实，而非既有回购计划的平均市场反应。
涨幅量级:没有可用于设定止盈幅度的高相似对齐先例；例行周度回购明细通常不应按新宣布回购计划的涨幅定价。
形态:未检索外部先例；即使历史回购披露曾短线上涨，也不能替代本次缺少新增授权或超预期执行的事实。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 77 ms
{"result": "search_processed_events:agent query=`novo nordisk company announcement no 55 2026 share repurchase | novo nordisk share repurchase programme september 2026 6-k transactions 7 september to 11 september | 诺和诺德 2026年9月 回`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 4,213 字
----- f6k_091426.htm -----
6-K
1
f6k_091426.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 14, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 14 September 2026 –
On 6 May 2026, Novo Nordisk initiated
a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April
2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part
of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period
from 6 May 2026 to 1 February 2027.
Since the announcement 07 September, the following transactions have been made:
Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement
17,275,000
5,221,774,293
7 September 2026
210,000
297.98
62,576,264
8 September 2026
210,000
295.53
62,062,090
9 September 2026
210,000
289.37
60,767,699
10 September 2026
210,000
288.08
60,496,529
11 September 2026
210,000
278.62
58,509,613
Accumulated under the programme
18,325,000
5,526,186,488
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated
above, Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The
total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As
of 11 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 33,084,179 B shares at an average share price of DKK
281.89 per B share equal to a transaction value of DKK 9,326,186,478.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Novo Nordisk Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Ida Schaap Melvold
Mads Berner Bruun
+45 3077 5649
+45 3075 2936
idmg@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
Alex Bruce (US)
+1 609 613 0568
+1 640 230 0276
fptr@novonordisk.com
axeu@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 55 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 14, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
6-K
1
f6k_091426.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 14, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 14 September 2026 –
On 6 May 2026, Novo Nordisk initiated
a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April
2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part
of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period
from 6 May 2026 to 1 February 2027.
Since the announcement 07 September, the following transactions have been made:
Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement
17,275,000
5,221,774,293
7 September 2026
210,000
297.98
62,576,264
8 September 2026
210,000
295.53
62,062,090
9 September 2026
210,000
289.37
60,767,699
10 September 2026
210,000
288.08
60,496,529
11 September 2026
210,000
278.62
58,509,613
Accumulated under the programme
18,325,000
5,526,186,488
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated
above, Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The
total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As
of 11 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 33,084,179 B shares at an average share price of DKK
281.89 per B share equal to a transaction value of DKK 9,326,186,478.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Novo Nordisk Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Ida Schaap Melvold
Mads Berner Bruun
+45 3077 5649
+45 3075 2936
idmg@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
Alex Bruce (US)
+1 609 613 0568
+1 640 230 0276
fptr@novonordisk.com
axeu@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 55 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 14, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。